Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Phase 3 Completed 371 enrolled EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.

Timeline

Start: 2015-12-28
Primary completion: 2017-09-14
Completion: 2019-11-13

Publications

Results Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Avelumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Irinotecan	Small molecule	150 mg/m2	—
Subject	Paclitaxel	Small molecule	80 mg/m2	—

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Summary

Timeline

Publications

Drugs

Indications